WHEAT RIDGE, Colo., Nov. 3 /PRNewswire-FirstCall/ -- GeneThera, Inc. (Pink Sheets: GTHR), As a service and responsibility to our shareholders, GeneThera is publicly outlining our strategy for the future of the company. GeneThera is making a pivotal shift from a Research and Development organization into a product marketing and revenue generating entity. The company strategy that we maintained from inception to our recent reverse split (July, 2008) had been one of research only. We focused all our energies, talent, and resources to the incubation and growth of new ideas in the realm of genetically engineered disease detection and vaccination. We feel that with recent announcements the company is positioned to move from a developmental stage to a product oriented stage RECENT DEVELOPMENTS Our recent developments include the progress we are making in regards to our Johne's Disease validation trials scheduled to begin in collaboration with the Universidad National Autonoma de Mexico, a prominent state university in Mexico City. Our joint venture with Nutricion Avanzada, (the joint venture created a new company Applied Genetics. Applied Genetics is the marketing arm of GeneThera for the Mexican marketing of our Johne's Disease testing service and subsequent Vaccine, (which is currently under development) has been in contact with several major ranchers throughout Mexico, and the overwhelming response from the ranchers has been an outcry for help in detecting and eliminating Johne's Disease which is running rampant in their herds. Government approval and recommendation is expected to occur quickly once the validation trials are complete. The validation trials should be complete within 3-4 months from start. We will be conducting paid testing on a limited basis during the validation trials. The recent signing of our agreement with STC.UNM (the technology development arm of The University of New Mexico) for the genetic vaccine they have developed and patented for E.Coli 0157:h7 has thrust GeneThera into the global spotlight. The vaccine acts on a genetic level to inhibit the growth and shedding of the deadly E.Coli 0157:h7 bacteria from cattle. The vaccine has already passed initial animal trials and is now set to enter the clinical trial phase. We are currently seeking partnerships for the completion of the clinical trials and subsequent taking of the finished vaccine to market. Due to the specific genetic makeup of the vaccine, we expect the clinical trials to be completed within 9-12 months from start. This is 3 to 5 times faster than a standard vaccine might take. GeneThera is working with The Goldsmith Group LLC for continued improvement of the company image and support for its shareholders. The Goldsmith Group is a private PR and Marketing firm whose members have extensive experience in the managing and marketing of both private and publicly traded firms throughout the US and Canada. They have been charged with improving the company website, creating new marketing and information materials for shareholders and partners, and presenting our company to a new group of potential shareholders. Comments from our Chairman GeneThera Chairman and CEO, DR. Tony Milici MD, PHD had this to say about the company's new direction; "We are very excited about all of the recent developments that have occurred at GeneThera. After all the time, energy, and money we have spent on development of new molecular assays and genetic vaccine research, it is very fulfilling to finally see the company making the turn to become a true revenue generating organization. We tip our hats and thank our shareholders for their support through those years of no dividends. We expect the entire outlook for the company and its shareholders to change in the very near future." Dr. Milici went on to state ... "We are now ready to start the validation trials for our Johne's Disease test in Mexico. We have received verbal commitments from many ranchers to test their entire herds already. The Johne's Disease issue is a very serious matter and these ranchers need our help. On the matter of the E.Coli 0157:h7 vaccine, we are most honored and flattered that the University of New Mexico chose us to complete the development and trials of their vaccine as well as bringing it to market. Dr. Boedeker and Dr. Zhu have done an excellent job creating a vaccine that has the ability to completely change the way we look at our food supply and the dangerous E.Coli bacteria. We do not expect to have any delays in starting the clinical trials or bringing the finished vaccine to market." With the change coming in the Presidential administration, GeneThera expects many of the previous testing requirements that had been considered by our government to be re-instated. This will only serve to better the position of GeneThera and its shareholders, as we have several testing methods to detect such pathogens as Mad Cow Disease, CWD, Johne's Disease, E.Coli 0157:h7, and others. These are all pathogens that have a serious affect on our food supply from both a safety and an economic standpoint. If/when testing for these pathogens becomes mandatory; GeneThera will already be in a position to capitalize on them. In conclusion, we at GeneThera want to once again thank our loyal shareholders for their continued support. We encourage you to contact us for more details on our plans and expectations for the future. About Johne's Disease Johne's (pronounced "Yo-nees") disease is a contagious bacterial disease of the intestinal tract. A German veterinarian first described the disease in a dairy cow in 1895; his name is used as the common name for the disease. The disease is also called paratuberculosis. Visit the history page for detailed information. Johne's disease occurs in a wide variety of animals, but most often in ruminants. Ruminants are hoofed mammals that chew their cud and have a four-chambered stomach. Some of the more common ruminants are: cattle, sheep, goats, deer, antelope, and bison. Johne's disease has been reported in all of these animals but is most commonly seen in dairy cattle. The result most commonly reported from infected cattle is a serious decline in herd milk production. The animal develops uncontrolled diarrhea and slowly wastes away to a point of death. The U.S. rate of dairy herd infection is similar to that reported in other countries using similar tests: Netherlands (55%), Belgium (22%), Austria (7%), England and Wales (17%), Denmark (47%), New Zealand (60%) and the state of Victoria in Australia (22%). The herd infection rate in U.S. beef cattle is lower although not many surveys have been reported. A 1997 survey found that: 7.8% of beef herds were infected using the same survey methods as for dairy cattle. Infection rates in beef cattle a most likely lower than in dairy cattle due to differences in animal husbandry practices. About E.Coli 057.h7 There are a variety of Escherichia coli bacteria present in nature. They are usually found in the intestines of healthy humans and healthy animals. Even though these bacteria offer beneficial properties, there are those variations, or strains that are pathogenic (have the ability to cause disease). Escherichia coli 0157:H7 is one particular strain that is "... an emerging cause of food borne illness ..." Symptoms such as bloody diarrhea and abdominal cramps may be observed or no such symptoms may appear. The elderly and children under five years old are highly susceptible to Hemolytic Uremic Syndrome, a disease in which red blood cells are destroyed and kidneys fail. According to the CDC " ... there may be about 70,000 infections with E. coli O157 each year in the United States. We can only estimate because we know that many infected people do not seek medical care, many do not submit a stool specimen for testing, and many labs do not test for STEC. The bacteria that make these toxins are called 'Shiga toxin producing' E. coli, or STEC for short." Shiga toxin is one of the most potent toxins known to man, so much so that the Centers for Disease Control and Prevention (CDC) lists it as a potential bioterrorist agent (CDC, n.d.). ABOUT GENETHERA, INC. GeneThera, Inc., is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the healthcare industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, Chronic Wasting Disease, E. coli 0157:H7 and Johne's disease, all diseases affecting cattle worldwide. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370. This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release. Dr. Tony Milici 303-463-6371 Goldsmith Group 303-838-4370 JR Dopkin & Associates 516-884-3200 DATASOURCE: GeneThera, Inc. CONTACT: Dr. Tony Milici of GeneThera, Inc., +1-303-463-6371; or Al Goldsmith of The Goldsmith Group LLC, +1-303-838-4370; or JR Dopkin & Associates, +1-516-884-3200, both for GeneThera, Inc.

Copyright